L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L- asparaginase as first exposure

C. Rizzari, M. Zucchetti, V. Conter, L. Diomede, A. Bruno, L. Gavazzi, M. Paganini, P. Sparano, L. Lo Nigro, M. Aricò, M. Milani, M. D'Incalci

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Purpose: The present study was aimed at investigating L-asparaginase (L- ASE) activity (in plasma) and L-asparagine (L-ASN) depletion (in plasma and CSF) in children with newly diagnosed acute lymphoblastic leukemia (ALL) exposed for the first time to different L-ASE products. Patients and methods: During the induction treatment of the AIEOP ALL 95 study, 62 patients were treated with either Erwinase® (n = 15), or E. coli medac® (n = 47) L-ASE products, given either i.m. or i.v., at the standard dosage of 10,000 IU/m2, q 3 days x 8 (first exposure). Results: Plasma and CSF L-ASN trough levels were undetectable in all cases, including those with L-ASE trough activity <50 mU/ml. L-ASE trough activity during the administration of medac® was however significantly higher when compared with that of Erwinase®. Conclusions: L-ASN depletion after a first exposure to standard doses of Erwinase® or medac® is obtained in virtually all patients. No differences are seen between the I.M. or I.V. administration routes but the medac® product is associated with a significantly higher enzyme activity in respect of Erwinase®. L-ASN levels may be undetectable also in patients with L-ASE trough activity levels <50 mU/ml, challenging the current opinion that an activity level of 100 mU/ml is needed to obtain L-ASN depletion.

Original languageEnglish
Pages (from-to)189-193
Number of pages5
JournalAnnals of Oncology
Volume11
Issue number2
DOIs
Publication statusPublished - 2000

Fingerprint

Erwinia
Asparaginase
Asparagine
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Escherichia coli
Enzymes

Keywords

  • ALL
  • Childhood
  • L-asparaginase
  • L-asparagine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L- asparaginase as first exposure. / Rizzari, C.; Zucchetti, M.; Conter, V.; Diomede, L.; Bruno, A.; Gavazzi, L.; Paganini, M.; Sparano, P.; Lo Nigro, L.; Aricò, M.; Milani, M.; D'Incalci, M.

In: Annals of Oncology, Vol. 11, No. 2, 2000, p. 189-193.

Research output: Contribution to journalArticle

Rizzari, C. ; Zucchetti, M. ; Conter, V. ; Diomede, L. ; Bruno, A. ; Gavazzi, L. ; Paganini, M. ; Sparano, P. ; Lo Nigro, L. ; Aricò, M. ; Milani, M. ; D'Incalci, M. / L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L- asparaginase as first exposure. In: Annals of Oncology. 2000 ; Vol. 11, No. 2. pp. 189-193.
@article{60792b6155d440ce804fb6245d0409f1,
title = "L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L- asparaginase as first exposure",
abstract = "Purpose: The present study was aimed at investigating L-asparaginase (L- ASE) activity (in plasma) and L-asparagine (L-ASN) depletion (in plasma and CSF) in children with newly diagnosed acute lymphoblastic leukemia (ALL) exposed for the first time to different L-ASE products. Patients and methods: During the induction treatment of the AIEOP ALL 95 study, 62 patients were treated with either Erwinase{\circledR} (n = 15), or E. coli medac{\circledR} (n = 47) L-ASE products, given either i.m. or i.v., at the standard dosage of 10,000 IU/m2, q 3 days x 8 (first exposure). Results: Plasma and CSF L-ASN trough levels were undetectable in all cases, including those with L-ASE trough activity <50 mU/ml. L-ASE trough activity during the administration of medac{\circledR} was however significantly higher when compared with that of Erwinase{\circledR}. Conclusions: L-ASN depletion after a first exposure to standard doses of Erwinase{\circledR} or medac{\circledR} is obtained in virtually all patients. No differences are seen between the I.M. or I.V. administration routes but the medac{\circledR} product is associated with a significantly higher enzyme activity in respect of Erwinase{\circledR}. L-ASN levels may be undetectable also in patients with L-ASE trough activity levels <50 mU/ml, challenging the current opinion that an activity level of 100 mU/ml is needed to obtain L-ASN depletion.",
keywords = "ALL, Childhood, L-asparaginase, L-asparagine",
author = "C. Rizzari and M. Zucchetti and V. Conter and L. Diomede and A. Bruno and L. Gavazzi and M. Paganini and P. Sparano and {Lo Nigro}, L. and M. Aric{\`o} and M. Milani and M. D'Incalci",
year = "2000",
doi = "10.1023/A:1008368916800",
language = "English",
volume = "11",
pages = "189--193",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "2",

}

TY - JOUR

T1 - L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L- asparaginase as first exposure

AU - Rizzari, C.

AU - Zucchetti, M.

AU - Conter, V.

AU - Diomede, L.

AU - Bruno, A.

AU - Gavazzi, L.

AU - Paganini, M.

AU - Sparano, P.

AU - Lo Nigro, L.

AU - Aricò, M.

AU - Milani, M.

AU - D'Incalci, M.

PY - 2000

Y1 - 2000

N2 - Purpose: The present study was aimed at investigating L-asparaginase (L- ASE) activity (in plasma) and L-asparagine (L-ASN) depletion (in plasma and CSF) in children with newly diagnosed acute lymphoblastic leukemia (ALL) exposed for the first time to different L-ASE products. Patients and methods: During the induction treatment of the AIEOP ALL 95 study, 62 patients were treated with either Erwinase® (n = 15), or E. coli medac® (n = 47) L-ASE products, given either i.m. or i.v., at the standard dosage of 10,000 IU/m2, q 3 days x 8 (first exposure). Results: Plasma and CSF L-ASN trough levels were undetectable in all cases, including those with L-ASE trough activity <50 mU/ml. L-ASE trough activity during the administration of medac® was however significantly higher when compared with that of Erwinase®. Conclusions: L-ASN depletion after a first exposure to standard doses of Erwinase® or medac® is obtained in virtually all patients. No differences are seen between the I.M. or I.V. administration routes but the medac® product is associated with a significantly higher enzyme activity in respect of Erwinase®. L-ASN levels may be undetectable also in patients with L-ASE trough activity levels <50 mU/ml, challenging the current opinion that an activity level of 100 mU/ml is needed to obtain L-ASN depletion.

AB - Purpose: The present study was aimed at investigating L-asparaginase (L- ASE) activity (in plasma) and L-asparagine (L-ASN) depletion (in plasma and CSF) in children with newly diagnosed acute lymphoblastic leukemia (ALL) exposed for the first time to different L-ASE products. Patients and methods: During the induction treatment of the AIEOP ALL 95 study, 62 patients were treated with either Erwinase® (n = 15), or E. coli medac® (n = 47) L-ASE products, given either i.m. or i.v., at the standard dosage of 10,000 IU/m2, q 3 days x 8 (first exposure). Results: Plasma and CSF L-ASN trough levels were undetectable in all cases, including those with L-ASE trough activity <50 mU/ml. L-ASE trough activity during the administration of medac® was however significantly higher when compared with that of Erwinase®. Conclusions: L-ASN depletion after a first exposure to standard doses of Erwinase® or medac® is obtained in virtually all patients. No differences are seen between the I.M. or I.V. administration routes but the medac® product is associated with a significantly higher enzyme activity in respect of Erwinase®. L-ASN levels may be undetectable also in patients with L-ASE trough activity levels <50 mU/ml, challenging the current opinion that an activity level of 100 mU/ml is needed to obtain L-ASN depletion.

KW - ALL

KW - Childhood

KW - L-asparaginase

KW - L-asparagine

UR - http://www.scopus.com/inward/record.url?scp=17544399852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17544399852&partnerID=8YFLogxK

U2 - 10.1023/A:1008368916800

DO - 10.1023/A:1008368916800

M3 - Article

C2 - 10761754

AN - SCOPUS:17544399852

VL - 11

SP - 189

EP - 193

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -